Using Biomarkers to Plan Adjuvant Therapy in Breast Cancer

Using Biomarkers to Plan Adjuvant Therapy in Breast Cancer (MS SPOC)

Originally presented June 27, 2018 as part of the UNC Cancer Network Medical and Surgical Oncology Lecture Series. This Self-Paced, Online Course expired July 29, 2019.

This is a Non-Credit course and does NOT offer continuing education credits.

Presenter

Lisa Carey, MD
Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Using Biomarkers to Plan Adjuvant Therapy in Breast Cancer

Dr. Carey will discuss the anatomic and genomic variables that impact on (neo)adjuvant decision-making in breast cancer and the current treatment algorithms that allow rational escalation and de-escalation of systemic therapy.

Learning Outcomes

  • Understand the roles of stage, hormone receptors, and biologic assays in determining systemic treatment and outcome.
  • Recognize the features that make a tumor more appropriate for neoadjuvant systemic therapy and the implications of this approach to therapy.
  • Determine the optimal regimens for triple negative, hormone receptor-positive, and HER2-positive breast cancer.

Credits Offered

  • 1.0 ANCC (CNE) hours of study.
  • 1 ASRT Category A CE Credit
  • 1.0 AMA PRA Category 1 Credit™
  • General Participation

Requirements

To receive credit for this course, you must:

  1. Watch a lecture video recording.
  2. Complete the lecture post test and obtain a passing score of 80% or higher.
  3. Complete the course evaluation.
  4. Select credit type.

Estimated course completion time: 1 hour

Disclosures

This activity has been planned and implemented under the sole supervision of the course directors, in association with the UNC Office of Continuing Professional Development (UNC CPD). Dr. Thomas Shea consults for Spectrum Pharma and receives research support from Millennium, Otsuka, GSK, BMS, Novartis and Seattle Genetics. Dr. James Coghill, MD, and CPD staff have no relevant financial relationships with commercial interests as defined by the ACCME.

The speaker, Lisa Carey, MD, is a principal investigator on clinical trials.

Accreditation

This is a Non-Credit course and does NOT offer continuing education credits.

Disclaimer

Please note: This course was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. Questions about personal health should always be referred to a physician or other health care professional.